Novo rapped by FDA for not reporting drug adverse effects
Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.
The critical role pharmacists play in continuity of care for...
One recommended approach to enhancing continuity in BD-I treatment is to deploy coordinated care teams.
NHS cleared to use Astellas' non-hormonal menopause drug
Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
Vertex preps FDA filing for IgAN drug after phase 3 readout
Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.
PHARMAP 2026: Where Pharma Meets Policy
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026)
7th Dermatology Drug Development Summit Europe
The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists
The PM Society Launches Pharmony to Support More Effective P...
The Pharmaceutical Marketing Society (PM Society) today announces the launch of Pharmony
EVERSANA Names Monica Avram Executive Vice President and Chi...
As chief legal officer and a member of the Executive Leadership Team, Monica Avram leads EVERSANA's global Legal and Compliance function.